EudraCT Number: 2021-002639-48 Sponsor Protocol Number: 54767414AMY2009 Start Date: 2022-07-25
Sponsor Name: Janssen-Cilag International N.V.
Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
Medical condition: Amyloid Light Chain Amyloidosis
Disease: Version SOC Term Classification Code Term Level
23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) IT (Ongoing) NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000049-34 Sponsor Protocol Number: ACT16753 Start Date: 2022-07-21
Sponsor Name: Sanofi-aventis recherche & développement
Full Title: A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...
Medical condition: Multiple sclerosis
Disease: Version SOC Term Classification Code Term Level
20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-005435-75 Sponsor Protocol Number: NN9838-4608 Start Date: 2022-07-21
Sponsor Name: Novo Nordisk A/S
Full Title: Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
Medical condition: Obesity, Overweight
Disease: Version SOC Term Classification Code Term Level
20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing) FI (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003664-28 Sponsor Protocol Number: Cp50PropofolPregabalin Start Date: 2022-07-18
Sponsor Name: Medical University of Vienna, Department of Anaesthesia, Critical Care and Pain Medicine
Full Title: The Effect of Pregabalin on the Cp50 of Propofol
Medical condition: This study aims to investigate the effect of a clinically used dose of Pregabalin on the Cp50 of propofol to provide more information to clinicians using this adjunctive drug in the perioperative s...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003900-42 Sponsor Protocol Number: MT-1186-A04 Start Date: 2022-07-15
Sponsor Name: Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
Full Title: A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following S...
Medical condition: Amyotrophic Lateral Sclerosis (ALS)
Disease: Version SOC Term Classification Code Term Level
21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003669-36 Sponsor Protocol Number: MS100070_0119 Start Date: 2022-07-14
Sponsor Name: Merck Healthcare KGaA
Full Title: A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with L...
Medical condition: Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy.
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Ongoing) DK (Ongoing) GR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001097-64 Sponsor Protocol Number: CVD19-ESCIN Start Date: 2022-07-14
Sponsor Name: UAB Švenčionių vaistažolės
Full Title: An open-label, randomized, parallel-controlled, phase II clinical trial to evaluate the tolerability, efficacy and safety of Aesculus Hippocastanum L seed extract in COVID-19 patients with mild pne...
Medical condition: COVID-19 patients with mild pneumonia
Disease: Version SOC Term Classification Code Term Level
23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: LT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005427-20 Sponsor Protocol Number: C4601003 Start Date: 2022-07-13
Sponsor Name: Pfizer Inc., 235 East 42nd Street, New York, NY 10017
Full Title: A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISE...
Medical condition: Prevention of Lyme disease caused by Borrelia species in individuals ≥5 years of age by active immunization
Disease: Version SOC Term Classification Code Term Level
20.0 10021881 - Infections and infestations 10025169 Lyme disease PT
Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) SE (Ongoing) FI (Ongoing) NL (Ongoing) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002163-22 Sponsor Protocol Number: NANORAY-312 Start Date: 2022-07-13
Sponsor Name: Nanobiotix SA
Full Title: A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for platinum-based Chemotherapy-ineligible Elderly P...
Medical condition: Locally Advanced Head & Neck Squamous Cell Carcinoma
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
Population Age: Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002344-73 Sponsor Protocol Number: LTS17367(KY1005-CT06) Start Date: 2022-07-12
Sponsor Name: Sanofi-aventis recherche & développement
Full Title: A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis who participated ...
Medical condition: Dermatitis atopic
Disease: Version SOC Term Classification Code Term Level
20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HU (Ongoing) ES (Ongoing)
Trial results: (No results available)

Medical Conditions

Sponsors and Collaborators

Drug Interventions